Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
In the Amyloidosis Program at Dana-Farber and Brigham and Women's Hospital, our dedicated experts work together across a range of specialty areas to coordinate fully integrated, personalized care. Team members are actively involved in research to advance
the treatment options and our understanding of this disease.
Giada Bianchi, MD, is on the faculty and is a physician scientist in the Hematologic Malignancies Division of Dana-Farber Cancer Institute. Her clinical interest is in plasma cell disorders, particularly AL amyloidosis, multiple myeloma, monoclonal gammopathy
of renal significance and multiple myeloma. In the laboratory, Bianchi's research focus is on mechanisms governing protein homeostasis in plasma cell disorders and their impact on AL amyloidosis and multiple myeloma pathogenesis and progression.
Rodney Falk, MD, is a world-renowned expert in cardiac amyloidosis. A cardiologist and amyloidosis specialist, Falk leads the Cardiac Amyloidosis Program at Brigham and Women's Hospital and brings his exceptional expertise in diagnosis and treatment —
as well as his passion for ongoing medical science discovery in this area — to patients with AL amyloidosis.
Jacob Laubach, MD, MPP
Albert Lam, MD Shannon Miller, NP
New Patient Appointments